Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy

키워드

참고문헌 (74)

1. Ben-Haim, S., "18F-FDG PET and PET", CT in the evaluation of cancer treatment response, 2009, pp.50, 88~99
2. Vander Heiden, M. G., "Understanding the Warburg effect: the metabolic requirements of cell proliferation", Science, 324, pp.1029~1033 (2009)
3. Warburg, O., "On respiratory impairment in cancer cells", Science, 124, pp.269~270 (1956)
4. Cairns, R. A., "Regulation of cancer cell metabolism", Nat. Rev. Cancer, 11, pp.85~95 (2011)
5. Levine, A. J., "The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes", Science, 330, pp.1340~1344 (2010)
6. Lunt, S. Y., "Aerobic glycolysis: meeting the metabolic requirements of cell proliferation", Annu. Rev. Cell Dev. Biol, 27, pp.441~464 (2011)
7. Wellen, K. E., "A two-way street: reciprocal regulation of metabolism and signalling", Nat. Rev. Mol. Cell Biol, 13, pp.270~276 (2012)
8. Vanhaesebroeck, B., "The emerging mechanisms of isoform- specific PI3K signalling", Nat. Rev. Mol. Cell Biol, 11, pp.329~341 (2010)
9. Engelman, J. A., "Targeting PI3K signalling in cancer: opportunities, challenges and limitations", Nat. Rev. Cancer, 9, pp.550~562 (2009)
10. Dang, C. V., "MYC-induced cancer cell energy metabolism and therapeutic opportunities", Clin. Cancer Res, 15, pp.6479~6483 (2009)
11. Wise, D. R., "Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction", Proc. Natl. Acad. Sci. U. S. A, 105, pp.18782~18787 (2008)
12. Gao, P., "c-Myc suppression of miR-23a", b enhances mitochondrial glutaminase expression and glutamine metabolism, 2009, pp.458, 762~765
13. Barthel, A., "Regulation of GLUT1 gene transcription by the serine", threonine kinase Akt1, 1999, pp.274, 20281~20286
14. Yun, J., "Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells", Science, 325, pp.1555~1559 (2009)
15. Ying, H., "Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism", Cell, 149, pp.656~670 (2012)
16. Schwartzenberg-Bar-Yoseph, F., "The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression", Cancer Res, 64, pp.2627~2633 (2004)
17. Bensaad, K., "TIGAR, a p53-inducible regulator of glycolysis and apoptosis", Cell, 126, pp.107~120 (2006)
18. Hu, W., "Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function", Proc. Natl. Acad. Sci. U. S. A, 107, pp.7455~7460 (2010)
19. Matoba, S., "p53 regulates mitochondrial respiration", Science, 312, pp.1650~1653 (2006)
20. Maiuri, M. C., "Autophagy regulation by p53", Curr. Opin. Cell Biol, 22, pp.181~185 (2010)
21. Mor, I., "Control of glycolysis through regulation of PFK1: old friends and recent additions", Cold Spring Harb. Symp. Quant. Biol, 76, pp.211~216 (2011)
22. Reid, M. A., "The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation", Mol. Cell, 50, pp.200~211 (2013)
23. Maddocks, O. D., "Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells", Nature, 493, pp.542~546 (2013)
24. Omar, H. A., "Energy restriction: stepping stones towards cancer therapy", Future Oncol, 8, pp.1503~1506 (2012)
25. Brown, J., "Effects of 2-deoxyglucose on carbohydrate metablism: review of the literature and studies in the rat", Metabolism, 11, pp.1098~1112 (1962)
26. Shutt, D. C., "2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells", Cancer Biol. Ther, 9, pp.853~861 (2010)
27. Rowe, I., "Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy", Nat. Med, 19, pp.488~493 (2013)
28. Dwarakanath, B. S., "Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects", J. Cancer Res. Ther, 5(Suppl 1), pp.S21~S26 (2009)
29. Wolf, A., "Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme", J. Exp. Med, 208, pp.313~326 (2011)
30. Clem, B. F., "Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer", Mol. Cancer Ther, 12, pp.1461~1470 (2013)
31. Nicholls, C., "Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component", Proc. Natl. Acad. Sci. U. S. A, 109, pp.13308~13313 (2012)
32. Goldberg, M. S., "Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression", J. Exp. Med, 209, pp.217~224 (2012)
33. Le, A., "Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression", Proc. Natl. Acad. Sci. U. S. A, 107, pp.2037~2042 (2010)
34. Liu, Y., "A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo", Mol. Cancer Ther, 11, pp.1672~1682 (2012)
35. Zhan, T., "Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins", J. Cell Biochem, 112, pp.849~859 (2011)
36. Sonveaux, P., "Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice", J. Clin. Invest, 118, pp.3930~3942 (2008)
37. Whitaker-Menezes, D., "Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts", Cell Cycle, 10, pp.1772~1783 (2011)
38. Clem, B., "Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth", Mol. Cancer Ther, 7, pp.110~120 (2008)
39. Telang, S., "Ras transformation requires metabolic control by 6-phosphofructo-2-kinase", Oncogene, 25, pp.7225~7234 (2006)
40. Kumagai, S., "Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells", Biochem. Biophys. Res. Commun, 365, pp.362~368 (2008)
41. Shoshan, M. C., "3-Bromopyruvate: targets and outcomes", J. Bioenerg. Biomembr, 44, pp.7~15 (2012)
42. Goldin, N., "Methyl jasmonate binds to and detaches mitochondria-bound hexokinase", Oncogene, 27, pp.4636~4643 (2008)
43. Birsoy, K., "MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors", Nat. Genet, 45, pp.104~108 (2013)
44. Mohanti, B. K., "Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I", II clinical trials on human cerebral gliomas, 1996, pp.35, 103~111
45. Mathupala, S. P., "Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy", Semin. Cancer Biol, 19, pp.17~24 (2009)
46. Hamanaka, R. B, "Targeting glucose metabolism for cancer therapy", J. Exp. Med, 209, pp.211~215 (2012)
47. Anastasiou, D, "Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis", Nat. Chem. Biol, 8, pp.839~847 (2012)
48. Cortes-Cros, M., "M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth", Proc. Natl. Acad. Sci. U. S. A, 110, pp.489~494 (2013)
49. DeBerardinis, R. J., "Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis", Proc. Natl. Acad. Sci. U. S. A, 104, pp.19345~19350 (2007)
50. Wise, D. R., "Glutamine addiction: a new therapeutic target in cancer", Trends Biochem. Sci, 35, pp.427~433 (2010)
51. Wang, J. B., "Targeting mitochondrial glutaminase activity inhibits oncogenic transformation", Cancer Cell, 18, pp.207~219 (2010)
52. Seltzer, M. J., "Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1", Cancer Res, 70, pp.8981~8987 (2010)
53. Yang, C., "Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling", Cancer Res, 69, pp.7986~7993 (2009)
54. Holubarsch, C. J., "A double- blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study", Clin. Sci. (Lond), 113, pp.205~212 (2007)
55. Downey, R. J., "Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection", J. Clin. Oncol, 22, pp.3255~3260 (2004)
56. Aykin-Burns, N., "Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation", Biochem. J, 418, pp.29~37 (2009)
57. Singh, D., "Optimizing cancer radiotherapy with 2-deoxy- d-glucose dose escalation studies in patients with glioblastoma multiforme", Strahlenther Onkol, 181, pp.507~514 (2005)
58. Raez, L. E., "A phase I dose-escalation trial of 2-deoxy- D-glucose alone or combined with docetaxel in patients with advanced solid tumors", Cancer Chemother. Pharmacol, 71, pp.523~530 (2013)
59. Kaplan, O., "Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism", Cancer Res, 50, pp.544~551 (1990)
60. Cay, O., "Inhibitory effect of 2-deoxy-D-glucose on liver tumor growth in rats", Cancer Res, 52, pp.5794~5796 (1992)
61. Cheong, J. H., "Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models", Mol. Cancer Ther, 10, pp.2350~2362 (2011)
62. Hardie, D. G., "AMP-activated", SNF1 protein kinases: conserved guardians of cellular energy, 2007, pp.8, 774~785
63. Hardie, D. G., "AMPK: a nutrient and energy sensor that maintains energy homeostasis", Nat. Rev. Mol. Cell Biol, 13, pp.251~262 (2012)
64. Chhipa, R. R., "Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress", Cell Signal, 22, pp.1554~1561 (2010)
65. Shaw, R. J., "Ras, PI(3)K and mTOR signalling controls tumour cell growth", Nature, 441, pp.424~430 (2006)
66. Beckers, A., "Chemical inhibition of acetyl-CoA carbox ylase induces growth arrest and cytotoxicity selectively in cancer cells", Cancer Res, 67, pp.8180~8187 (2007)
67. Yong-Joo Ahn, "AMP-activated protein kinase: implications on ischemic diseases", BMB Reports, 45(9), pp.489~495 (2012), 생화학분자생물학회
68. Graham, N. A., "Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death", Mol. Syst. Biol, 8, pp.589~ (2012)
69. Choo, A. Y., "Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply", Mol. Cell, 38, pp.487~499 (2010)
70. Laderoute, K. R., "5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments", Mol. Cell Biol, 26, pp.5336~5347 (2006)
71. Ben Sahra, I., "Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells", Cancer Res, 70, pp.2465~2475 (2010)
72. Evans, J. M., "Metformin and reduced risk of cancer in diabetic patients", BMJ, 330, pp.1304~1305 (2005)
73. Zhou, G., "Role of AMP-activated protein kinase in mechanism of metformin action", J. Clin. Invest, 108, pp.1167~1174 (2001)
74. Saito, S., "Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation", Cancer Res, 69, pp.4225~4234 (2009)

관련 논문AI추천